Shares of ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) added 92.82% by the end of trading session at $4.2. For the current quarter, the 1 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$1.2/share, which would compare with -$2.4 in the year-ago quarter. The net percentage change is 1267.63% over the last 12 months. The trading range in the same period had a highest hit of $14.8 while lowest level was $1.83. At the moment the price is 154.37% above its 50-day moving average and 648.29% above its 200-day moving average.

ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) on December 14, 2016 announced that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of the Board of Directors. Dr. Gringeri has served as ImmunoCellular’s Senior Vice President of Strategic Resources since August 2013, and has led the implementation of the Company’s clinical and regulatory strategy for the ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, as well as the ICT-121 phase 1 trial in recurrent glioblastoma. The appointment of Dr. Gringeri follows the decision by Andrew Gengos to resign the position of Chief Executive Officer. Mr. Gengos will continue to play an active role with the Company as a member of the Board of Directors, leveraging his broad experience in corporate strategy, financing, and business development. John Yu, MD, ImmunoCellular’s founder, will also continue to provide support to Dr. Gringeri and the management team in his continuing role on the Board of Directors.

Dr. Gringeri joined ImmunoCellular Therapeutics in August 2013. He has more than 25 years of executive experience in the pharmaceutical and biotechnology industry, having successfully led multiple functions and cross-functional teams throughout his career, including in the areas of clinical, regulatory and commercial planning and operations, finance, licensing and alliance management. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer, responsible for all preclinical, clinical and regulatory activities. Previously, Dr. Gringeri served as Chief Operating Officer for Amsterdam Molecular Therapeutics, where he was responsible for corporate strategy and operations, business development, building the company’s commercial capability, and played a key role in its initial public offering. Dr. Gringeri worked with Amgen for 15 years in a series of executive leadership roles. Dr. Gringeri was the Vice President, Product Development, responsible for the successful development and commercialization of ARANESP® (darbepoetin alfa). Dr. Gringeri holds a PhD in pharmacology from the University of Rochester and has authored multiple scientific publications.

GenVec, Inc. (NASDAQ:GNVC) last exchanged hands at a price $8.79/share, registering a gain of 76.86%. Among 1 Wall Street analysts tracked by Thomson/First Call, the average PT for GNVC is $15 but some of them are predicting the price to move at the $15 level. If the most optimistic analysts are correct, the expected total return from the current price would be 70.65. The number of shares traded in most recent trading day was 17.27M shares which averages 99.18K shares a day. Its previous fifty two week high was $10.44 and moved up 22.08% over the same time frame, currently having a market cap around $22.33 million. Shares have risen 114.39% over the trailing six months. At the moment, the stock trades 162.47% above its 50-day moving average and 62.04% above its 200-day moving average.

GenVec, Inc. (NASDAQ:GNVC) on January 5, 2017 announced that it has entered into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. If the option is exercised, the license will allow broad utilization of technology developed by David T. Curiel, M.D., Ph.D., professor of radiation oncology and Jeffrey Arbeit, M.D., professor of surgery at Washington University School of Medicine. GenVec plans to initially focus on research utilizing the technology to develop treatments for hemophilia.